Advances in PD-1/PD-L1 inhibitors in treatment of non-small cell lung cancer

Lung cancer is the leading cause of cancer-related deaths around the world. Although targeted therapy has significantly prolonged the survival of patients with non-small cell lung cancer (NSCLC), the prognosis of NSCLC remains unsatisfactory.Recently, immune checkpoint inhibitors of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have made a breakthrough in the treatment of NSCLC. This review aims to summarize the current status quo and prospect of immune checkpoint inhibitor PD-1/PD-L1 in treatment of NSCLC.